Skip to main content
Erschienen in: Medical Oncology 2/2008

01.06.2008 | Case

Systemic chemotherapy of TS-1 and cisplatin for gastric signet-ring cell carcinoma presenting as cardiac tamponade

verfasst von: Hitoshi Kusaba, Masahiko Fujihara, Ryuichi Nagashima, Yoshikazu Kaji, Eishi Baba, Shuji Nakano

Erschienen in: Medical Oncology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

A 59-year-old man complaining of dyspnea, anterior chest oppression, and hypotension was diagnosed to have cardiac tamponade due to massive pericardial effusion. A cytological analysis of the pericardial effusion disclosed adenocarcinoma. An endoscopic study revealed gastric cancer in the lesser curvature wall of the middle body of the stomach, and signet-ring cell carcinoma was confirmed histologically. The gastric cancer was complicated by malignant pericardial effusion, and metastasis to the mediastinal lymph nodes. The patient was treated with pericardiocentesis followed by systemic chemotherapy consisting of TS-1 and cisplatin (CDDP). After 5 months, pericardial effusion disappeared and the primary gastric tumor decreased in size. Our experience suggests that the systemic chemotherapy of TS-1 and CDDP may be effective for controlling advanced gastric signet-cell carcinoma accompanied by malignant pericardial effusion.
Literatur
1.
Zurück zum Zitat Tabata Y, Nakato H, Nakamura Z, Sasaki K, Shoji K, Yokoyama H, et al. Metastatic cancer to the heart—A clinicopathological analysis of 64 autopsy cases (in Japanese). Kokyu To Junkan (Respiration and Circulation) 1983;31:569–73. Tabata Y, Nakato H, Nakamura Z, Sasaki K, Shoji K, Yokoyama H, et al. Metastatic cancer to the heart—A clinicopathological analysis of 64 autopsy cases (in Japanese). Kokyu To Junkan (Respiration and Circulation) 1983;31:569–73.
2.
Zurück zum Zitat Richard SF, Juan BV, Nai-San W. Cardiac tamponade as a presentation of extracardiac malignancy. Cancer 1980;45:1697–704.CrossRef Richard SF, Juan BV, Nai-San W. Cardiac tamponade as a presentation of extracardiac malignancy. Cancer 1980;45:1697–704.CrossRef
3.
Zurück zum Zitat Moriyama A, Murata I, Kuroda T, Yoshikawa I, Tabaru A, Ogami Y, Ostuki M. Pericardiac metastasis from advanced gastric cancer. J Gastroenterol 1995;30:512–6.PubMedCrossRef Moriyama A, Murata I, Kuroda T, Yoshikawa I, Tabaru A, Ogami Y, Ostuki M. Pericardiac metastasis from advanced gastric cancer. J Gastroenterol 1995;30:512–6.PubMedCrossRef
4.
Zurück zum Zitat Sakai Y, Minouchi K, Ohta H, Annen Y, Sugimoto T. Cardiac tamponade originating from primary gastric signet ring cell carcinoma. J Gastroenterol 1999;34:250–2.PubMedCrossRef Sakai Y, Minouchi K, Ohta H, Annen Y, Sugimoto T. Cardiac tamponade originating from primary gastric signet ring cell carcinoma. J Gastroenterol 1999;34:250–2.PubMedCrossRef
5.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.PubMedCrossRef
6.
Zurück zum Zitat Yano T, Yokoyama H, Inoue T, Takanashi N, Asoh H, Ichinose Y. A simple technique to manage malignant pericardial effusion with a local instillation of bleomycin in non-small cell carcinoma of the lung. Oncology 1994;51:507–9.PubMedCrossRef Yano T, Yokoyama H, Inoue T, Takanashi N, Asoh H, Ichinose Y. A simple technique to manage malignant pericardial effusion with a local instillation of bleomycin in non-small cell carcinoma of the lung. Oncology 1994;51:507–9.PubMedCrossRef
7.
Zurück zum Zitat Liu G, Crump M, Goss PE, Dancey J, Shepherd FA. Prospective compariso of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol 1996;14:3141–7.PubMed Liu G, Crump M, Goss PE, Dancey J, Shepherd FA. Prospective compariso of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol 1996;14:3141–7.PubMed
8.
Zurück zum Zitat Colleoni M, Martinelli G, Beretta F, Marone C, Gallino A, Fontana M, et al. Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen. J Clin Oncol 1998;16:2371–6.PubMed Colleoni M, Martinelli G, Beretta F, Marone C, Gallino A, Fontana M, et al. Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen. J Clin Oncol 1998;16:2371–6.PubMed
9.
Zurück zum Zitat Moriya T, Takiguchi Y, Tabeta H, Watanabe R, Kimura H, Nagao K, et al. Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. Br J Cancer 2000;83:858–62.PubMedCrossRef Moriya T, Takiguchi Y, Tabeta H, Watanabe R, Kimura H, Nagao K, et al. Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. Br J Cancer 2000;83:858–62.PubMedCrossRef
10.
Zurück zum Zitat Murad AM, Santiago FF, Petroianu A, Rocha PRS, Rodrigues MAG, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37–41.PubMedCrossRef Murad AM, Santiago FF, Petroianu A, Rocha PRS, Rodrigues MAG, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37–41.PubMedCrossRef
11.
Zurück zum Zitat Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587–91.PubMed Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587–91.PubMed
12.
Zurück zum Zitat Wils JA, Klein HO, Wagener JT, Bleiberg H, Reis A, Kolsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin—a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827–31.PubMed Wils JA, Klein HO, Wagener JT, Bleiberg H, Reis A, Kolsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin—a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827–31.PubMed
13.
Zurück zum Zitat Vanhoefer U, Rouger P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final result of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin, versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 2000;81:2648–57. Vanhoefer U, Rouger P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final result of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin, versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 2000;81:2648–57.
14.
Zurück zum Zitat Kim NK, Park YS, Heo DS. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advancer gastric cancer. Cancer 1993;71:3813–8.PubMedCrossRef Kim NK, Park YS, Heo DS. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advancer gastric cancer. Cancer 1993;71:3813–8.PubMedCrossRef
15.
Zurück zum Zitat Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: theJapan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54–9.PubMedCrossRef Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of 5-fluorouracil alone versus 5-fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin C in patients with unresectable advanced gastric cancer: theJapan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54–9.PubMedCrossRef
16.
Zurück zum Zitat Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late-phase II study of novel oral fluoropyrimidine anticancer drug S-1 in advanced gastric cancer patients. Eur J Cancer 1998;34:1715–20.PubMedCrossRef Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late-phase II study of novel oral fluoropyrimidine anticancer drug S-1 in advanced gastric cancer patients. Eur J Cancer 1998;34:1715–20.PubMedCrossRef
17.
Zurück zum Zitat Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of TS-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191–7.PubMedCrossRef Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of TS-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191–7.PubMedCrossRef
18.
Zurück zum Zitat Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Randomized phase III study of 5-fluorouracil alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Proc Am Soc Clin Oncol 2007;25:200S (abstr 4513). Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Randomized phase III study of 5-fluorouracil alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Proc Am Soc Clin Oncol 2007;25:200S (abstr 4513).
19.
Zurück zum Zitat Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M, et al. Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. Proc Am Soc Clin Oncol 2007; 25:201S (abstr 4514). Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M, et al. Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. Proc Am Soc Clin Oncol 2007; 25:201S (abstr 4514).
Metadaten
Titel
Systemic chemotherapy of TS-1 and cisplatin for gastric signet-ring cell carcinoma presenting as cardiac tamponade
verfasst von
Hitoshi Kusaba
Masahiko Fujihara
Ryuichi Nagashima
Yoshikazu Kaji
Eishi Baba
Shuji Nakano
Publikationsdatum
01.06.2008
Verlag
Humana Press Inc
Erschienen in
Medical Oncology / Ausgabe 2/2008
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-007-9010-6

Weitere Artikel der Ausgabe 2/2008

Medical Oncology 2/2008 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.